Lucira Health (Lucira Health) EBIT per Share : $-3.54 (TTM As of Sep. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Lucira Health EBIT per Share?

Lucira Health's EBIT per Share for the three months ended in Sep. 2022 was $-3.13. Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2022 was $-3.54.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Lucira Health's EBIT per Share or its related term are showing as below:

LHDXQ's 3-Year EBIT Growth Rate is not ranked ^*
in the Medical Devices & Instruments industry.
Industry Median: 5.65
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Lucira Health's EBIT for the three months ended in Sep. 2022 was $-125.9 Mil.

Lucira Health EBIT per Share Historical Data

The historical data trend for Lucira Health's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lucira Health EBIT per Share Chart

Lucira Health Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

EBIT per Share

-0.80

-0.54

-1.04

-1.86

Lucira Health Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
EBIT per Share	Get a 7-Day Free Trial									-0.71	-0.21	0.33	-0.53	-3.13

Lucira Health EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Lucira Health's EBIT per Share for the fiscal year that ended in Dec. 2021 is calculated as

	EBIT per Share		(A: Dec. 2021 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-64.807	/	34.769
=	-1.86

Lucira Health's EBIT per Share for the quarter that ended in Sep. 2022 is calculated as

	EBIT per Share		(Q: Sep. 2022 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-125.899	/	40.216
=	-3.13

EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.54

Lucira Health (OTCPK:LHDXQ) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Lucira Health EBIT per Share Related Terms

Thank you for viewing the detailed overview of Lucira Health's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Lucira Health (Lucira Health) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lucira Health Inc (OTCPK:LHDXQ) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

1412 62nd Street, Emeryville, CA, USA, 94608

Website

https://www.lucirahealth.com

Lucira Health Inc is a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits. It has developed a testing platform that produces high-complexity-laboratory-accurate molecular testing in a single-use and user-friendly test kit that is powered by two AA batteries and fit in the palm of a hand. The company's initial focus is within respiratory diseases, and initially for COVID-19 and influenza Types A and B indications.

Executives

Anthony Joseph Allen	officer: Chief Operations Officer	1412 62ND STREET, EMERYVILLE CA 94608
Epq Llc, Lcovd Safe Ps	other: Less than 10% owner	9650 GATEWAY DRIVE, SUITE 200, RENO NV 89521
Chad Boeding	other: CEO of 10% owner	ONE LOMBARD STREET, SUITE 200, SAN FRANCISCO CA 94111
Epiq Capital Group, Llc	10 percent owner	ONE LOMBARD STREET, SUITE 200, SAN FRANCISCO CA 94111
Epq Llc, Lcovd Ps	10 percent owner	9650 GATEWAY DRIVE, SUITE 200, RENO NV 89521
Epq Llc, Lflu Ps	other: Less than 10% owner	9650 GATEWAY DRIVE, SUITE 200, RENO NV 89521
Epq Llc, Ltest Ps	other: Less than 10% Owner	9650 GATEWAY DRIVE, SUITE 200, RENO NV 89521
Richard Clavano Narido	officer: Interim CFO	12 HANSEN CT, MORAGA CA 94556
Ghazi Kashmolah	officer: Ex. VP &Chief Quality Officer	1412 62ND STREET, EMERYVILLE CA 94608
Kevin Walter Collins	officer: Chief Revenue Officer	C/O LUCIRA HEALTH, INC., 1412 62ND STREET, EMERYVILLE CA 94608
Dan George	officer: CFO and Treasurer	1412 62ND STREET, EMERYVILLE CA 94608
Erik T. Engelson	director, officer: President and Chief Executive	1412 62ND STREET, EMERYVILLE CA 94608
Debkishore Mitra	director, officer: Chief Technology Officer	1412 62ND STREET, EMERYVILLE CA 94608
Tamanna Prashar	officer: Vice President	1412 62ND STREET, EMERYVILLE CA 94608
Alison Mccauley	director	C/O LUCIRA HEALTH, INC., 1412 62ND STREET, EMERYVILLE CA 94608